Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics
Strategic Profile
NRx leverages a specialized NMDA platform targeting treatment-resistant psychiatric conditions with high unmet medical needs. The company combines biopharmaceutical development with clinic infrastructure, positioning itself uniquely at the intersection of drug development and mental health service delivery through its clinic network expansion strategy.
Cyborg Score Rationale
The company has significant clinical milestones and regulatory progress (NDA filing for NRX-100 in March 2025, anticipated NRX-101 NDA filing), plus strong partnerships including licensing discussions offering $300M+ in milestones. However, it faces substantial financial constraints with minimal revenue, negative cash flow ($10.6M operating loss), a market cap of only $52.1M, and challenging liquidity (0.15 current ratio).
Top Insights
Advanced regulatory pipeline: NRX-100 NDA filed for suicidal depression treatment; NRX-101 pursuing Breakthrough Designation for bipolar depression with anticipated PDUFA dates before end of 2025
Clinic network expansion: Building HOPE Therapeutics clinic network for interventional psychiatry, attempting to create a differentiated integrated care model combining pharmacotherapy with clinical infrastructure
Strategic licensing discussions: In advanced discussions with major pharma for NRX-100 distribution rights worth $300M+ in milestones plus double-digit royalties, providing potential non-dilutive financing
Financial distress signals: Severe liquidity constraints with market cap of $52.1M, zero trailing revenue, $25.1M net loss, and current ratio of 0.15 indicating short-term solvency concerns
Named Competitors
Spravato (esketamine) — FDA-approved intranasal ketamine for treatment-resistant depression
Therapeutic platforms in PTSD/depression — Clinical-stage therapies for severe psychiatric conditions
(March 2025) Initiated New Drug Application filing for NRX-100 (IV Ketamine) for suicidal depression treatment
(March 2025) Advanced NRX-101 toward NDA filing for Accelerated Approval under Breakthrough Designation for bipolar depression in akathisia-risk patients
(Q4 2024) Reduced operational losses by 45% quarter-over-quarter; retired debt and secured new investor alignment
(Q1 2025) Pursuing preservative-free ketamine ANDA filing and citizen petition to remove benzethonium chloride from IV ketamine presentations
Open the full interactive NRx Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.